Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 5Unknown 2Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 1Hepatitis 1Chemical and Drug Induced Liver Injury 1Adenomatous Polyposis Coli 1Adenoma 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Ursodeoxycholic Acid × Clear all
NCT04810156 2022-12-14

I-HEP

Herlev Hospital

Phase 2 Unknown
60 enrolled

Hepatitis, Neoplasms, Chemical and Drug Induced Liver Injury

NCT00134758 2009-07-29

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Unknown
90 enrolled
Gastrointestinal

Adenoma, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡